Welcome to our dedicated page for Viatris news (Ticker: VTRS), a resource for investors and traders seeking the latest updates and insights on Viatris stock.
Viatris Inc. (NASDAQ: VTRS) is a global healthcare company that bridges the gap between generics and branded medicines, aiming to address healthcare needs more comprehensively worldwide. Formed in November 2020 by the merger of Upjohn, a subsidiary of Pfizer, and Mylan, Viatris leverages its vast portfolio to provide high-quality medications to approximately 1 billion patients annually across more than 165 countries. The company’s operations span 10 major therapeutic areas, with a strategic focus on dermatology, ophthalmology, and gastroenterology.
Viatris boasts an extensive product lineup, including around 1,400 generic pharmaceuticals and several branded medications like Lipitor, Norvasc, Lyrica, and Viagra. Generics and biosimilars form about 40% of its sales, while legacy products contribute to the remaining 60%. The company is also a key supplier of antiretroviral therapies, which nearly 50% of HIV/AIDS patients in developing countries rely on.
In 2023, Viatris continued to make strides with significant developments. It announced positive results from the YUPELRI® Phase III clinical trial in China for COPD treatment, paving the way for regulatory approval anticipated in mid-2024. The company also entered a substantial R&D collaboration with Idorsia Ltd, acquiring global rights to two promising Phase 3 assets: selatogrel, for acute myocardial infarction, and cenerimod, for systemic lupus erythematosus. Additionally, Viatris launched RYZUMVI™, an FDA-approved eye drop for reversing pharmacologically-induced dilation, further expanding its ophthalmology portfolio.
Financially, Viatris demonstrated robust performance with consistent operational revenue growth. The company reported a strong 2023, meeting its financial guidance, and executed strategic initiatives like the divestiture of its Women's Healthcare Business and API business in India. Viatris also maintained a solid cash flow, allowing it to return capital to shareholders through dividends and share repurchases, reinforcing its commitment to shareholder value.
Headquartered in the U.S., with major centers in Pittsburgh, Shanghai, and Hyderabad, Viatris employs around 30,000 people dedicated to advancing global health. For more information, visit viatris.com.
Viatris (NASDAQ: VTRS) announced the publication of Phase 2b CARE study results for cenerimod in treating moderate-to-severe systemic lupus erythematosus (SLE). Published in Lancet Rheumatology, the study showed that cenerimod 4 mg demonstrated meaningful improvement in SLE disease activity compared to placebo. The trial involved 427 patients aged 18-75 years, randomized across different dosage groups.
Key findings include a -4.04 change from baseline in mSLEDAI-2K score for the 4 mg group, with stronger results in patients with high IFN-1 gene expression. The drug was well-tolerated with mostly mild to moderate adverse events. Additional biomarker data published in the Annals of the Rheumatic Diseases further characterized cenerimod's mechanism of action. These results have informed the ongoing Phase 3 OPUS program.
Viatris (VTRS) reported Q3 2024 financial results with total revenues of $3.8 billion and operational revenue growth of ~3% on a divestiture-adjusted basis. Key highlights include new product revenues of $133 million, U.S. GAAP net earnings of $95 million, and adjusted EBITDA growth of ~4% to $1.3 billion. The company repaid ~$1.9 billion of debt and expects to achieve its long-term gross leverage target of ~3.0x by year-end. Viatris entered an exclusive licensing agreement for sotagliflozin, expanding its cardiovascular disease portfolio. The company reaffirms its 2024 full-year outlook, expecting revenue growth of ~2% on a divestiture-adjusted operational basis.
Viatris (NASDAQ: VTRS) has announced its Board of Directors approved a quarterly dividend of $0.12 per share on November 4, 2024. The dividend will be distributed on December 13, 2024, to shareholders recorded as of November 22, 2024. This dividend applies to all issued and outstanding shares of the company's common stock.
Viatris (NASDAQ: VTRS) has been named to Forbes' World's Top Companies for Women 2024 List, in collaboration with Statista. The selection process involved surveys of approximately 100,000 women across 37 countries, collecting over 750,000 data points. The evaluation was based on three key criteria: Employer Brand Score, Public Opinion Score, and Leadership Score.
The recognition highlights Viatris' commitment to fostering diverse talent and creating an inclusive workplace culture. The company's women's Employee Resource Group, EmpoWer, has shown significant growth and impact in supporting female employees. This achievement follows other recent recognitions, including Forbes' World's Best Employers 2024, TIME's World's Most Sustainable Companies 2024, and USA Today's America's Climate Leaders 2024.
Viatris (Nasdaq: VTRS) has announced its participation in two major healthcare conferences in November 2024. The company will attend the UBS Global Healthcare Conference on November 12 at the Terranea Resort in California, with a fireside chat scheduled for 8:45 a.m. PT. Additionally, Viatris will participate in the Jefferies London Healthcare Conference on November 21 at the Waldorf Hilton Hotel in London, with a session at 10:30 a.m. GMT.
Both events will feature fireside chats with Viatris executives and will be accessible via live webcasts at investor.viatris.com, with archived versions available for time after the events.
Viatris Inc. (Nasdaq: VTRS) has entered an exclusive licensing agreement with Lexicon Pharmaceuticals for sotagliflozin in all markets outside the U.S. and Europe. Sotagliflozin, approved by the FDA in May 2023, reduces cardiovascular risks in adults with heart failure or type 2 diabetes mellitus, chronic kidney disease, and other cardiovascular risk factors.
This agreement leverages Viatris' expertise in cardiovascular diseases and its Global Healthcare Gateway®. Viatris will pay Lexicon an upfront payment of $25 million, with additional potential contingent payments including regulatory milestones, sales milestones, and tiered royalties ranging from low-double-digit to upper-teens on annual net sales. Viatris will handle regulatory and commercialization activities in licensed territories, while Lexicon will provide clinical and commercial supply of sotagliflozin.
Viatris has released its 2023 Sustainability Report, highlighting extensive efforts in India to address critical health and social needs. Key initiatives include:
- Supporting Akshaya Vidya, a supplementary education program for underprivileged children.
- Developing a watershed in Ranga Reddy District to boost groundwater and agricultural productivity.
- Partnering with Sportz Village Foundation to promote fitness among children in Hyderabad.
In cancer care, Viatris, in collaboration with Tata Memorial Center, has screened over 8 million people for oral cancer, expanding from six districts to all 34 in Maharashtra and to six other states. The Healthy Liver Healthy Delhi program has provided over 30,000 liver health screenings since 2017. Viatris also supports sustainable farming practices and is working to address tuberculosis (TB) through multiple community programs, benefiting over 80,000 people in 2023.
Viatris, a global healthcare company, has released its 2023 Sustainability Report highlighting efforts to reduce packaging materials. Key initiatives include:
- Reducing paper use by 90 metric tons at oral-solid dose manufacturing sites
- Cutting 2 metric tons of plastic and 5 metric tons of wood through bulk packaging optimization
- Replacing 88 metric tons of plastic with polythene bags
- Reducing plastic use by 18 metric tons through shrink bundle film optimization
The company is also exploring e-labeling, implementing PCTFE mitigation in blister packaging, and pursuing carton-less initiatives. Viatris is working on harmonizing packaging across markets, including the use of quadrilingual packs to reduce the need for individual language-specific bottles. In Cairo, Egypt, the facility has started reusing empty supply carton boxes, saving four tons annually.
Viatris Inc. (NASDAQ: VTRS) announced positive top-line results from its Phase 3 study of EFFEXOR® (venlafaxine) in Japanese adults with Generalized Anxiety Disorder (GAD). The study met its primary objective, demonstrating superiority of EFFEXOR® over placebo in anxiolytic effects at 8 weeks. All seven secondary efficacy endpoints were also met.
EFFEXOR® was generally well tolerated, with low discontinuation rates due to adverse events and no serious adverse events observed. The company plans to submit to the Pharmaceuticals and Medical Devices Agency (PMDA) in 2025. This study is significant as there are currently no approved treatments for GAD in Japan.
Viatris Inc. (NASDAQ:VTRS), a global healthcare company, has been named to Forbes' list of World's Best Employers 2024 for the fourth consecutive year. This recognition, presented by Forbes and Statista, is based on an independent survey of over 300,000 participants across 50 countries.
Andrew Enrietti, Chief People Officer at Viatris, attributed this achievement to the company's strong culture that prioritizes employee well-being, inclusivity, diversity, growth opportunities, and work-life balance. The selection process involved participants rating their willingness to recommend their employer and reviewing various aspects of employment.
This recognition follows Viatris' inclusion in other prestigious lists such as TIME's World's Most Sustainable Companies 2024, USA Today's America's Climate Leaders 2024, and 3BL's 100 Best Corporate Citizens of 2023. The company has also received Great Place to Work® certifications and Top Employers certifications in multiple countries.
FAQ
What is the current stock price of Viatris (VTRS)?
What is the market cap of Viatris (VTRS)?
What is Viatris Inc.?
What products does Viatris offer?
What are Viatris' key therapeutic areas?
What recent collaborations has Viatris announced?
How did Viatris perform financially in 2023?
Where is Viatris headquartered?
What is YUPELRI®?
What is the significance of RYZUMVI™?
What is the mission of Viatris?
How many people does Viatris employ?
